PD-L1 22C3 CPS in paired primary breast cancer and lung metastasis
- PMID: 40498245
- DOI: 10.1007/s10549-025-07757-9
PD-L1 22C3 CPS in paired primary breast cancer and lung metastasis
Abstract
Purpose: This study aimed to evaluate the expression of PD-L1 22C3 in primary breast cancer and lung metastasis tissues using the Combined Positive Score (CPS) and to investigate the concordance and differences between them.
Methods: Immunohistochemical staining for PD-L1 22C3 was performed on 52 paired cases of primary breast cancer and lung metastases. The CPS was measured and analyzed for comparison.
Results: The PD-L1 positivity rate (CPS ≥ 10) was 13.5% in primary breast cancers and 30.8% in lung metastases. The overall percent agreement (OPA) for PD-L1 CPS between primary tumors and lung metastases was 78.8%, with a positive percent agreement (PPA) of 85.7% and a negative percent agreement (NPA) of 77.8%. The mean CPS was 2.69 ± 6.67 (mean ± SD) in primary breast cancers and 7.67 ± 14.49 (mean ± SD) in lung metastases, with a significantly higher CPS observed in lung metastases (p < 0.001). The primary cause of discordance, where PD-L1 was negative in the primary tumor but positive in the metastasis, was the presence of PD-L1-positive alveolar macrophages predominantly located around or within the metastatic tumor.
Conclusion: PD-L1 22C3 demonstrated approximately 80% concordance between primary breast cancers and lung metastases; however, discordance was mainly attributable to the presence of inherently PD-L1-positive peritumoral and/or intratumoral alveolar macrophages.
Keywords: Breast cancer; Lung metastasis; PD-L1.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors have no conflicts of interest to declare. Ethical approval: The study adhered to the principles of the Declaration of Helsinki and obtained approval from the Institutional Review Board of Yonsei University Severance Hospital (IRB number: IRB number: 4-2024-0276). Consent to participate: Due to the retrospective nature of the study, patient consent was exempted by the Institutional Review Board of Yonsei University Severance Hospital.
References
-
- Gennari A, Conte P, Rosso R et al (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104(8):1742–1750. https://doi.org/10.1002/cncr.21359 - DOI - PubMed
-
- Gligorov J, Lotz JP (2008) Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer. Breast Cancer Res Treat 112(Suppl 1):53–66. https://doi.org/10.1007/s10549-008-0232-x - DOI - PubMed
-
- Wu Q, Li J, Zhu S et al (2017) Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget 8(17):27990–27996. https://doi.org/10.18632/oncotarget.15856 - DOI - PubMed - PMC
-
- Adams S, Loi S, Toppmeyer D et al (2019) Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol 30(3):405–411. https://doi.org/10.1093/annonc/mdy518 - DOI - PubMed
-
- Cortes J, Rugo HS, Cescon DW et al (2022) Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 387(3):217–226. https://doi.org/10.1056/NEJMoa2202809 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials